ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate technology. The Company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. Leading healthcare companies have licensed rights to use ImmunoGen's technology to develop novel anticancer therapies, and Roche's marketed product, Kadcyla, utilizes ImmunoGen's ADC technology.
Company Growth (employees)
Type
Public
HQ
Waltham, US
Founded
1981
Size (employees)
308 (est)
ImmunoGen was founded in 1981 and is headquartered in Waltham, US

ImmunoGen Office Locations

ImmunoGen has offices in Waltham, Norwood and Brentwood
Waltham, US (HQ)
830 Winter St
Norwood, US
333 Providence Hwy

ImmunoGen Data and Metrics

ImmunoGen Financial Metrics

ImmunoGen's revenue was reported to be $28.5 m in Q1, 2017 which is a 272% increase from the previous period.
USD

Revenue (Q1, 2017)

28.5 m

Net income (Q1, 2017)

(17.3 m)

EBIT (Q1, 2017)

(12.9 m)

Market capitalization (22-Sep-2017)

570.9 m

Cash (31-Mar-2017)

126.6 m
ImmunoGen's current market capitalization is $570.9 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

59.9 m85.5 m60 m

Revenue growth, %

43%(30%)

R&D expense

148.1 m

General and administrative expense

36.9 m
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2017

Revenue

6.9 m13.2 m48.3 m11.4 m14.9 m18 m19.7 m7.7 m28.5 m

R&D expense

38.3 m28 m27.6 m25.7 m35.1 m38.2 m36.1 m32.9 m32.9 m

General and administrative expense

6 m7.1 m6.9 m7 m8.3 m8.1 m11.2 m9.5 m8.1 m

Operating expense total

44.3 m35.1 m34.5 m32.7 m43.5 m46.3 m47.3 m42.4 m41 m
USDFY, 2014FY, 2015FY, 2016

Cash

142.3 m278.1 m245 m

Accounts Receivable

1.9 m5.1 m883 k

Inventories

3 m2.9 m907 k

Current Assets

150.8 m292.2 m254.8 m
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2017

Cash

164.1 m121.8 m106.6 m111.8 m247.8 m212.3 m182.9 m196 m126.6 m

Accounts Receivable

36 k1.8 m3.1 m754 k6.8 m803 k104 k316 k3.9 m

Inventories

2.5 m2.1 m1.9 m2.7 m1.2 m1.5 m908 k2 m3.2 m

Current Assets

172.3 m128.3 m114.4 m119.1 m262 m223.2 m193.3 m207.3 m142.1 m
USDFY, 2014FY, 2015FY, 2016

Net Income

(71.4 m)(60.7 m)(144.8 m)

Depreciation and Amortization

4.6 m5.5 m5.3 m

Accounts Receivable

(1.9 m)(3.2 m)4.2 m

Inventories

(2.2 m)15 k2 m
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2017

Net Income

(44.9 m)(22.3 m)(8.6 m)(30.3 m)(33.7 m)(67 m)(98.9 m)(44.7 m)(17.3 m)

Depreciation and Amortization

3.4 m1.4 m2.8 m4.2 m1.1 m2.4 m3.8 m1.5 m1.5 m

Accounts Receivable

(36 k)58 k(1.2 m)1.1 m(1.7 m)4.3 m5 m567 k(1.9 m)

Inventories

(1.8 m)835 k1 m248 k1.7 m1.4 m2 m(1.1 m)(1 m)
USDY, 2017

Revenue/Employee

92.5 k
Show all financial metrics

ImmunoGen Market Value History

ImmunoGen Job Categories

ImmunoGen Median Salaries

Source: 17 public H-1B filings from ImmunoGen

Traffic Overview of ImmunoGen

ImmunoGen Online and Social Media Presence

ImmunoGen Company Life and Culture

You may also be interested in